Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity
2012
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI